Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
598 people get CORT articles and Market Currents by email alert.
Get email alerts on CORT »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
Marketwire (May 2, 2013)
-
Marketwire (Apr 26, 2013)
-
-
Marketwire (Mar 7, 2013)
-
-
Marketwire (Feb 12, 2013)
-
-
-
-
-
-
Marketwire (Oct 31, 2012)
-
Marketwire (Oct 15, 2012)
-
-
-
3 Liquid Biotech Stocks With Impressive Growth ProjectionsZetaKap • Sun, Aug 12, 2012
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
-
Corcept Stock Continues To Rally On Weight Loss NewsH.S. Ayoub • Wed, Jun 27, 2007 -
Corcept's Crash Not Necessarily What it SeemsFredric Cohen, M.D. • Mon, Aug 28, 2006
-
-
-
-
-
-
-
3 Liquid Biotech Stocks With Impressive Growth ProjectionsZetaKap • Sun, Aug 12, 2012
-
-
-
Hedge Funds Are Buying These 10 High-Growth Biotech StocksKapitall • Sat, Jul 14, 2012 -
8 High Growth Small Caps With Analyst LoveZetaKap • Wed, Jun 20, 2012
-
-
-
-
7 Stocks Deeply Discounted From Target Price Seeing Short CoveringKapitall • Tue, Mar 27, 2012
-
-
-
-
-
-
Marketwire (May 2, 2013)
-
Marketwire (Apr 26, 2013)
-
Marketwire (Mar 7, 2013)
-
Marketwire (Feb 12, 2013)
-
Marketwire (Oct 31, 2012)
-
Marketwire (Oct 15, 2012)
-
Marketwire (Aug 7, 2012)
-
Marketwire (Jul 2, 2012)
-
Marketwire (Jul 2, 2012)
-
Marketwire (May 3, 2012)
-
Marketwire (Mar 26, 2012)
-
at MarketWatch.com (Feb 21, 2012)
CORT vs. ETF Alternatives
Company Description
Currently, there's no company description for CORT.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Friday, May 3, 6:50 AM Corcept Therapeutics (CORT): Q1 EPS of -$0.10 misses by $0.01. Revenue of $1.72M misses by $0.76M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Thursday, March 7, 5:23 PM More on Corcept Therapeutics (CORT): Q4 is largely in-line on EPS, but a bit shy on the revenue side. Net profit declined Y/Y, as the drug developer racked up higher SG&A expenses due to increased staffing, consultancy and other professional services costs related to the rollout of Korlym. Comment! [Healthcare, Earnings]
- Thursday, March 7, 5:17 PM Corcept Therapeutics (CORT): Q4 EPS of -$0.09 in-line. Revenue of $1.4M misses by $0.1M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Friday, January 4, 4:05 PM Corcept Therapeutics (CORT) ramps up another 15% today, rising for a second day following an upgrade yesterday by Piper Jaffray and analysts at Janney Capital beginning coverage of the stock with a Buy rating and a $3 price target. CORT climbed just over 10% on Thursday to close at $1.63 a share, its best finish since early November. Comment! [Healthcare, On the Move]
-
Tuesday, December 4, 2012, 12:45 PM
Midday top 10 gainers: ALDA +54%. SINO +29%. CYCC +17%. LTBR +12%. CORT +12%. SAB +11%. EDMC +10%. CPGI +11%. PRIS +10%. ACLS +10%.
Midday top 10 Losers: UEPS -56%. GERN -24%. EXA -22%. CUR -20%. SSN -19%. PPHM -16%. IQNT -18%. PBY -14%. GURE -12%. LEDS -12%. 3 Comments [On the Move] -
Tuesday, August 7, 2012, 9:10 AM
Premarket gainers: USHS +37%. BSFT +24%. FOSL +21%. LOPE +18%. BVSN +10%. ZLCS +10%. VRNG +9%. IHG +8%. CIM +6%. NOK +6%. MGM +5%. DCTH +5%.
Losers: WMS -20%. LEAP -18%. NIHD -16%. ELN -11%. CORT -10%. HEK -9%. DUF -8%. Comment! [On the Move] -
Monday, July 2, 2012, 9:10 AM
Premarket gainers: CELL +64%. LNCR +21%. AMPE +17%. ATPG +13%. WFR +9%. AMLN +9%. MU +7%.
Losers: ANH -6%. OREX -5%. CORT -5%. Comment! [On the Move] - Monday, July 2, 2012, 8:38 AM Corcept Therapeutics (CORT) intends to sell 11M shares to raise funds for R&D and other purposes. Corcept develops drugs for severe psychiatric and metabolic disorders, including Cushing's syndrome and psychotic depression. Shares -5.35% premarket. (PR) Comment! [Healthcare, On the Move]
- Friday, June 29, 2012, 12:41 PM ThinkEquity initiates coverage on a slew of drug developers with a Buy rating this morning: Navidea (NAVB +3.7%), BioMarin (BMRN +4.5%), Corcept Therapeutics (CORT +4%), Medivation (MDVN +5.2%), Amicus Theraputics (FOLD +2%), Raptor Pharmaceuticals (RPTP +0.2%), Synageva BioPharma (GEVA +3.2%), Aegerion (GEVA +3.7%). Comment! [Healthcare, On the Move]
- Thursday, March 22, 2012, 11:01 AM Leerink Swann says the pricing for Corcept's (CORT -0.8%) Korlym is higher than expected at $186 per 300mg tablet, which should help offset its caution regarding patient numbers. The drug developer announced this morning it will begin shipping Korlym starting April 11. 1 Comment [Healthcare]
-
Tuesday, February 21, 2012, 9:07 AM
Premarket gainers: CORT +61%. THLD +59%. PBH +24%. CTIC +11%. CHG +10%. STM +8%. SWC +8%. JASO +7%. WYNN +6%. IVAN +6%. SSN +5%. YGE +5%. HL +4%. IRE +4%. TSL +4%. FRO +3%. M +3%. HD +3%. DANG +3%. CS +3%. STP +3%. NG +3%.
Losers: GTXI -39%. CHTP -13%. WFT -11%. CTRP -9%. CIE -5%. NBG -5%. RIG -5%. CIEN -4%. WMT -3%. Comment! [On the Move] - Tuesday, February 21, 2012, 6:56 AM Corcept Therapeutics (CORT) continues to skyrocket after landing FDA approval for its Korlym oral medicine used to treat Cushing's syndrome patients. The firm expects to launch of Korlym within the next two to three months, with consensus sales forecasts for the drug running as high as $409M by 2016. Shares +68.1% premarket. Comment! [On the Move, Healthcare]
- Friday, February 17, 2012, 4:45 PM Corcept Therapeutics (CORT), a specialty drug company that hasn’t generated revenue since 2009, wins FDA approval for its Korlym treatment that uses the active ingredient of the abortion pill RU-486 to treat Cushing’s Syndrome. Shares +42.5% after a trading halt. Comment! [Healthcare, On the Move]
- Thursday, June 30, 2011, 11:56 AM Corcept Therapeutics (CORT -8.7%) sinks on heavy volume, despite regulators accepting its application to market Corlux as a treatment for Cushing's Syndrome. After final approval, Corcept will have seven years to market the drug exclusively. Comment! [On the Move, Healthcare]
- Monday, June 6, 2011, 8:53 AM A massive data dump this morning and over the weekend from biotech firms reporting results from various drug trials and regulatory updates. Stocks on the move as a result: Cell Therapeutics (CTICD, press release) +2.8%, Exelixis (EXEL, PR) -2.2%, Incyte (INCY, PR) +3%, Corcept Therapeutics (CORT, PR) -4.8%, United Therapeutics (UTHR, PR) -6.1%, RXi Pharmaceuticals (RXII, PR) +17.7%, Impax Labs (IPXL, PR) -3.3%. Comment! [Healthcare, On the Move]
-
Scott Matusow
Trade and buy Alert, Bought $CORT at 2.00, target opinion per chart = $2.50 short term. - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
anonymous#12
CORT, korlym sales seemed pretty weak taking in consideration it is a orphan drug indication. Neutral. - View all 0 replies
-
ZetaKap
3 Liquid Biotech Stocks With Impressive Growth Projections http://bit.ly/NrEmOe $ANIK $CBPO $CORT @ZetaKap - View all 0 replies
-
- View all 0 replies
-
Michael Clark
BUY: PCLN, TXT, BCRX, JDSU. VIX. SHORT: SCHN, XOMA, CORT, AOBI. Momentum still down in markets. http://seekingalpha.com/p/j7sh - View all 5 replies
-
Michael Clark: He's a clown. Actually the markets move up and down like a breathing process. The talking head say this caused that and that caused this.
-
Michael Clark: In truth, the market breathed out; and will soon again breathe in. European system isn't fixed. They've said their in charge before.
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
LATEST REPLIES
-
Michael Clark
BUY: PCLN, TXT, BCRX, JDSU. VIX. SHORT: SCHN, XOMA, CORT, AOBI. Momentum still down in markets. http://seekingalpha.com/p/j7sh - View all 5 replies
-
Michael Clark: He's a clown. Actually the markets move up and down like a breathing process. The talking head say this caused that and that caused this.
-
Michael Clark: In truth, the market breathed out; and will soon again breathe in. European system isn't fixed. They've said their in charge before.